The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The role of pomalidomide-dexamethasone in patients with multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the combination of lenalidomide and dexamethasone in multiple myeloma. Dr Cerchione explains that a recent retrospective study showed that this doublet was effective in heavily pre-treated patients who are not eligible for hospital-based treatment, and emphasizes the role of adequate supportive care in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
